JP2017517508A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517508A5
JP2017517508A5 JP2016568679A JP2016568679A JP2017517508A5 JP 2017517508 A5 JP2017517508 A5 JP 2017517508A5 JP 2016568679 A JP2016568679 A JP 2016568679A JP 2016568679 A JP2016568679 A JP 2016568679A JP 2017517508 A5 JP2017517508 A5 JP 2017517508A5
Authority
JP
Japan
Prior art keywords
amino
alkyl
group
hydroxy
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016568679A
Other languages
English (en)
Japanese (ja)
Other versions
JP6672176B2 (ja
JP2017517508A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/031400 external-priority patent/WO2015179308A1/en
Publication of JP2017517508A publication Critical patent/JP2017517508A/ja
Publication of JP2017517508A5 publication Critical patent/JP2017517508A5/ja
Application granted granted Critical
Publication of JP6672176B2 publication Critical patent/JP6672176B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016568679A 2014-05-19 2015-05-18 ボロン酸誘導体およびその治療的使用 Active JP6672176B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000400P 2014-05-19 2014-05-19
US62/000,400 2014-05-19
PCT/US2015/031400 WO2015179308A1 (en) 2014-05-19 2015-05-18 Boronic acid derivatives and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2017517508A JP2017517508A (ja) 2017-06-29
JP2017517508A5 true JP2017517508A5 (enExample) 2018-07-05
JP6672176B2 JP6672176B2 (ja) 2020-03-25

Family

ID=54554593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568679A Active JP6672176B2 (ja) 2014-05-19 2015-05-18 ボロン酸誘導体およびその治療的使用

Country Status (11)

Country Link
US (1) US9963467B2 (enExample)
EP (1) EP3145936B1 (enExample)
JP (1) JP6672176B2 (enExample)
KR (1) KR20170007448A (enExample)
CN (1) CN106459096B (enExample)
AU (1) AU2015264418A1 (enExample)
BR (1) BR112016026291A2 (enExample)
CA (1) CA2947041A1 (enExample)
EA (1) EA201691988A1 (enExample)
MX (1) MX2016015093A (enExample)
WO (1) WO2015179308A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
CA2893943C (en) 2012-12-07 2021-03-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6346904B2 (ja) * 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
EP3882252B1 (en) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2015284307A1 (en) * 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TWI759267B (zh) 2015-07-02 2022-04-01 美商地平線罕見醫學製藥有限責任公司 Ado抗性半胱胺類似物及其用途
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP7060245B2 (ja) 2016-06-30 2022-04-26 キューペックス バイオファーマ, インコーポレイテッド ボロン酸誘導体およびその治療的使用
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
TW201841642A (zh) * 2017-04-28 2018-12-01 日商大日本住友製藥股份有限公司 雜環衍生物
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019009369A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 イミン誘導体
TW201906616A (zh) * 2017-07-06 2019-02-16 日商大日本住友製藥股份有限公司 醯胺衍生物
CA3078627A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102679411B1 (ko) * 2018-04-27 2024-07-01 스미토모 파마 가부시키가이샤 옥소 치환 화합물
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
AU2019386849B2 (en) * 2018-11-29 2025-07-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
TW202038941A (zh) * 2018-12-28 2020-11-01 日商大日本住友製藥股份有限公司 烷基取代化合物
US20230144152A1 (en) 2019-06-19 2023-05-11 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
WO2021079984A1 (ja) * 2019-10-25 2021-04-29 大日本住友製薬株式会社 新規置換縮環型化合物
KR20220156047A (ko) * 2020-03-18 2022-11-24 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 치료적 용도

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
AU8140898A (en) 1997-06-13 1998-12-30 Northwestern University Inhibitors of beta-lactamases and uses therefor
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
AU2190400A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
US6747030B1 (en) 1999-09-25 2004-06-08 Smithkline Beecham P.L.C. Piperazine derivatives as 5-HT1B antagonists
CA2388077A1 (en) 1999-10-28 2001-05-03 James M. Balkovec Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
WO2002022137A1 (en) 2000-09-12 2002-03-21 Shoichet Brian K β-LACTAM ANALOGS AND USES THEREFOR
EP1322648B1 (en) 2000-09-14 2005-06-29 Pantherix Limited 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
AU2002243508A1 (en) 2001-01-10 2002-07-24 Bristol-Myers Squibb Company Patent Department Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
CA2488785C (en) 2002-09-11 2012-07-03 Kureha Chemical Industry Company, Limited Amine compound and use thereof
EP2325226A1 (en) 2002-10-30 2011-05-25 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AU2003300358A1 (en) 2002-12-20 2004-07-22 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
BRPI0415185A (pt) 2003-10-10 2006-11-28 Pfizer Prod Inc 2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
AU2006214247C1 (en) 2005-02-16 2012-11-08 Anacor Pharmaceuticals, Llc Boron-containing small molecules
CA2680693A1 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
US9184428B2 (en) 2005-03-15 2015-11-10 Uchicago Argonne Llc Non-aqueous electrolytes for lithium ion batteries
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
EP2484680B1 (en) 2005-12-07 2013-06-26 Basilea Pharmaceutica AG Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors
CA2642583C (en) 2006-02-16 2016-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
MX2009009918A (es) 2007-03-23 2009-10-19 Basilea Pharmaceutica Ag Medicamentos combinados para el tratamiento de infecciones bacterianas.
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
BRPI0820532A2 (pt) * 2007-11-13 2012-07-10 Protez Pharmaceuticals Inc inibidores de beta-lactamase
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2285384A4 (en) 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2009139834A1 (en) 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
WO2010144338A1 (en) 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
JP2013500974A (ja) 2009-07-28 2013-01-10 アナコール ファーマシューティカルズ,インコーポレイテッド 三置換ホウ素含有分子
WO2011103686A1 (en) 2010-02-26 2011-09-01 Viswanatha , Sundaramma CEPHALOSPORIN DERIVATIVES USEFUL AS β-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
EA029521B1 (ru) 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
US8822516B2 (en) 2010-06-10 2014-09-02 Technion Research & Development Foundation Limited Process for the preparation of iodides
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
HUE027317T2 (en) 2010-10-26 2016-10-28 Mars Inc Boronates as arginase inhibitors
TW201221518A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
JP6129203B2 (ja) 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
CA2862710A1 (en) 2012-01-09 2013-07-18 University Of Tromso Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2893943C (en) * 2012-12-07 2021-03-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6324409B2 (ja) * 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
US9241947B2 (en) * 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) * 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2014204045B2 (en) * 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US8999885B2 (en) 2013-01-09 2015-04-07 General Electric Company Methods of activating charcoal resulting from biomass gasification
JP6346904B2 (ja) * 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9127024B2 (en) 2013-03-15 2015-09-08 Intrexon Corporation Boron-containing diacylhydrazines
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3882252B1 (en) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
US20160339045A1 (en) 2015-04-24 2016-11-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections

Similar Documents

Publication Publication Date Title
JP2017517508A5 (enExample)
JP2016505619A5 (enExample)
JP2016509594A5 (enExample)
JP2017526636A5 (enExample)
JP2009535307A5 (enExample)
JP2016512844A5 (enExample)
JP2011504935A5 (enExample)
JP2010530881A5 (enExample)
JP2010513322A5 (enExample)
JP2020507582A5 (enExample)
JP2009518317A5 (enExample)
JP2013531029A5 (enExample)
JP2006509749A5 (enExample)
DE2714880A1 (de) Cephemderivate und verfahren zu ihrer herstellung
JP2013500314A5 (enExample)
RU2019123404A (ru) Производное пиримидина
JP2007516983A5 (enExample)
JP2005537312A5 (enExample)
ES2691805T3 (es) Medicamento para el tratamiento de una enfermedad ocular
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
WO2008015280A3 (de) Wässrige wirkstoffkonzentrate mit herbizider wirkung
CA2487542A1 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
JP2014500265A5 (enExample)
RU2006140989A (ru) 2-пиридилзамещенные имидазолы как ингибиторы рецепторов alk4